Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis
Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis. Methods: In this single-center retrospective cohort study, a total of 20 consecutive patients underwent LA because of their clinical sympt...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2024
|
| In: |
Cancers
Year: 2024, Jahrgang: 16, Heft: 1, Pages: 1-17 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers16010058 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers16010058 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/16/1/58 
|
| Verfasserangaben: | Kiavasch Mohammad Nejad Farid, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow and Anita Schmitt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1888155191 | ||
| 003 | DE-627 | ||
| 005 | 20240703174528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240508s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers16010058 |2 doi | |
| 035 | |a (DE-627)1888155191 | ||
| 035 | |a (DE-599)KXP1888155191 | ||
| 035 | |a (OCoLC)1443675782 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Farid, Kiavasch |d 1997- |e VerfasserIn |0 (DE-588)1282170538 |0 (DE-627)1837796548 |4 aut | |
| 245 | 1 | 0 | |a Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis |c Kiavasch Mohammad Nejad Farid, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow and Anita Schmitt |
| 264 | 1 | |c 2024 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 08.05.2024 | ||
| 520 | |a Purpose: We aimed to identify subsets of patients who benefit from emergency LA and to establish a therapeutic algorithm for AML patients with hyperleukocytosis. Methods: In this single-center retrospective cohort study, a total of 20 consecutive patients underwent LA because of their clinical symptoms. Overall survival (OS) analysis was conducted using the Kaplan-Meier plot method. Univariate and multivariate analyses (using multiple logistic regression) were performed. At the time of diagnosis, all patients received a standard diagnostic workup for AML including FLT3-ITD mutational analysis. Results: FLT3-ITD mut AML patients receiving LA had a median OS of 437 days (range 5-2379 days) with a corresponding 14-day survival of 92.3%, while FLT3 wt AML patients displayed a significantly lower median OS of only 5 days (range 1-203 days) with a corresponding 14-day survival of 14.3% (p = 0.0001). Conclusions: Among patients with clinical symptoms of leukostasis, the subset of FLT3-ITD mut AML patients showed a better outcome with lower early mortality after emergency LA. Based on these observations, we established a therapeutic algorithm for AML patients with hyperleukocytosis. | ||
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a cytoreduction | |
| 650 | 4 | |a early mortality | |
| 650 | 4 | |a hyperleukocytosis | |
| 650 | 4 | |a leukapheresis | |
| 650 | 4 | |a leukostasis | |
| 700 | 1 | |a Sauer, Tim |d 1981- |e VerfasserIn |0 (DE-588)138282013 |0 (DE-627)601099516 |0 (DE-576)307058166 |4 aut | |
| 700 | 1 | |a Schmitt, Michael |d 1966- |e VerfasserIn |0 (DE-588)133177173 |0 (DE-627)538000600 |0 (DE-576)299672921 |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Schmitt, Anita |d 1969- |e VerfasserIn |0 (DE-588)141722495 |0 (DE-627)630587752 |0 (DE-576)325593892 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 16(2024), 1, Artikel-ID 58, Seite 1-17 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:1 |g elocationid:58 |g pages:1-17 |g extent:17 |a Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers16010058 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/16/1/58 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240508 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 141722495 |a Schmitt, Anita |m 141722495:Schmitt, Anita |d 910000 |d 910100 |d 50000 |e 910000PS141722495 |e 910100PS141722495 |e 50000PS141722495 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 5 |y j | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 133177173 |a Schmitt, Michael |m 133177173:Schmitt, Michael |d 910000 |d 910100 |d 50000 |e 910000PS133177173 |e 910100PS133177173 |e 50000PS133177173 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 998 | |g 138282013 |a Sauer, Tim |m 138282013:Sauer, Tim |d 910000 |d 910100 |e 910000PS138282013 |e 910100PS138282013 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 1282170538 |a Farid, Kiavasch |m 1282170538:Farid, Kiavasch |d 50000 |e 50000PF1282170538 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1888155191 |e 452170025X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis","title":"Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresis"}],"origin":[{"dateIssuedDisp":"2024","dateIssuedKey":"2024"}],"note":["Gesehen am 08.05.2024"],"id":{"doi":["10.3390/cancers16010058"],"eki":["1888155191"]},"recId":"1888155191","relHost":[{"recId":"614095670","name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["614095670"],"zdb":["2527080-1"],"issn":["2072-6694"]},"pubHistory":["1.2009 -"],"note":["Gesehen am 27.05.2020"],"origin":[{"dateIssuedDisp":"2009-","publisher":"MDPI","dateIssuedKey":"2009","publisherPlace":"Basel"}],"title":[{"title":"Cancers","title_sort":"Cancers"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Symptomatic patients with hyperleukocytic FLT3-ITD mutated acute myeloid leukemia might benefit from leukapheresisCancers","language":["eng"],"part":{"text":"16(2024), 1, Artikel-ID 58, Seite 1-17","issue":"1","pages":"1-17","year":"2024","volume":"16","extent":"17"}}],"physDesc":[{"extent":"17 S."}],"name":{"displayForm":["Kiavasch Mohammad Nejad Farid, Tim Sauer, Michael Schmitt, Carsten Müller-Tidow and Anita Schmitt"]},"person":[{"role":"aut","given":"Kiavasch","display":"Farid, Kiavasch","family":"Farid"},{"display":"Sauer, Tim","family":"Sauer","given":"Tim","role":"aut"},{"family":"Schmitt","display":"Schmitt, Michael","given":"Michael","role":"aut"},{"display":"Müller-Tidow, Carsten","family":"Müller-Tidow","given":"Carsten","role":"aut"},{"family":"Schmitt","display":"Schmitt, Anita","given":"Anita","role":"aut"}],"language":["eng"]} | ||
| SRT | |a FARIDKIAVASYMPTOMATI2024 | ||